Spots Global Cancer Trial Database for Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients
Official Title: Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation
Study ID: NCT01719536
Conditions
Study Description
Brief Summary: The purpose of this study is to compare icotinib with induction and maintenance chemotherapy in the first-line treatment of advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation.
Detailed Description: This study is designed to evaluate the efficacy and safety of icotinib and pemetrexed-based first-line induction and maintenance chemotherapy in advanced lung adenocarcinoma with EGFR-mutation，primary endpoint is progress-free survival，second endpoints include overall survival, time to progression, and so on.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The First Affiliated Hospital of Anhui Medical Univercity, Hefei, Anhui, China
Chinese People's Liberation Army (PLA) General Hospital, Beijing, Beijing, China
Beijing Hospital for Chest Tumors & Tuberculosis Diseases, Beijing, Beijing, China
Xinqiao Hospital, The Third Military Medical University, Chongqing, Chongqing, China
The First Affiliated Hospital Of Guangzhou Medical Collage, Guangzhou, Guangdong, China
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Hebei Provincal Tumor Hospital, Shijiazhuang, Hebei, China
Harbin Medical Univercity Cancer Hospital, Harbin, Heilongjiang, China
Henan Provincal Tumor Hospital, Zhengzhou, Henan, China
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
Jiangsu Provincal Tumor Hospital, Nanjing, Jiangsu, China
The First Bethune Hospital of Jilin Univercity, Changchun, Jilin, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
Shandong Cancer Hospital, Jinan, Shandong, China
Shanghai Chest Hospital Affiliated to Shanghai Jiaotong Univercity, Shanghai, Shanghai, China
Zhongshan Hospital Affiliated to Fudan Univercity, Shanghai, Shanghai, China
Changhai Hospital, The Second Military Medical University, Shanghai, Shanghai, China
Xijing Hospital, Xian, Shanxi, China
Sichuan Provincal Tumor Hospital, Chengdu, Sichuan, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Contact Details
Name: Shi Yuankai, M.D.
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
